Interpace Biosciences (IDXG) investor relations material

Company overview and business model

• Provides esoteric molecular diagnostic testing and pathology services to help clinicians assess cancer risk in patients with indeterminate biopsies; current commercial focus is thyroid tests ThyGeNEXT and ThyraMIR v2 after discontinuing PancraGEN in May 2025.

• Revenue comes from clinical-service test sales and reimbursement by government and commercial payers, plus direct client billings; LabCorp was the largest customer for the thyroid tests in 2025 and H1 2026.

• ThyGeNEXT analyzes DNA and RNA mutations; ThyraMIR v2 uses microRNA analysis to refine malignancy risk. The combined platform is used in 93% of patients and reports 99% NPV and 94% PPV at 30% disease prevalence.

• Strategy centers on growing test volumes, expanding payer coverage, improving lab efficiency, marketing existing assays, developing new tests and selectively partnering or acquiring complementary technologies.

Financial performance and metrics

• Thyroid-only pro forma revenue rose from $20.3 million in 2022 to $34.8 million in 2025, a 19.7% CAGR; volumes increased from 25,200 to 36,200 over the period.

• Thyroid-only pro forma gross profit was $21.2 million in 2025; EBIT was $3.1 million and adjusted EBITDA was $4.4 million, versus $18.1 million, $1.7 million and $2.3 million, respectively, in 2024.

• 2025 thyroid test volume mix and ASP: Medicare 12%/$3,746; Medicare Advantage 10%/$2,663; Medicaid 3%/$482; commercial 36%/$1,620; client and patient groups 39%/$2,096.

• As of June 30, 2026, cash and cash equivalents were $2.688 million actual and $20.617 million pro forma for the offering; pro forma total capitalization was $40.236 million.

Use of proceeds and capital allocation

• Estimated net proceeds are $17.9 million at the assumed $6.50 midpoint, or $20.8 million if the 465,000-share over-allotment option is exercised in full, after underwriting discounts and estimated expenses.

• Proceeds are intended for working capital, capital expenditures and general corporate purposes; potential uses include developing pancreatic cyst and Barrett’s Esophagus tests or investing in complementary businesses, technologies, products or assets.

• Pending deployment, proceeds are intended for capital-preservation investments such as short-term interest-bearing obligations, investment-grade instruments, certificates of deposit or U.S. government obligations.